BIODISTRIBUTION AND TRAFFICKING OF NORMAL AND ACTIVATED BLOOD MONOCYTES

这项研究旨在评估人口贩运模式 静脉注射给人类的自体单核细胞。 单核细胞将从正常志愿者或癌症患者身上移除 用逆流分离和提纯患者 离心式淘洗。纯化的单核细胞要么是 在4度(正常单核细胞)下放置4小时或被激活 通过接触重组人伽马干扰素。细胞将会 用铟-111标记并静脉回输给 分别为正常供者或患者。正常献血者或癌症 患者将首先接受静脉输注自体血 正常单核细胞；如果没有发现不良反应，捐赠者 或者患者可以接受自体伽马干扰素的输注- 四周后激活单核细胞。频繁的血样会 在接下来的96小时内从患者或捐赠者体内取出 以确定注入的细胞平衡的速率 血单核细胞的边际池(如果存在)，以及 确定这些细胞从 血流进入网状内皮系统和其他 纸巾。此外，多个地区性闪烁图将 以确定这些标记的单核细胞是否优先 定位于任何一个器官系统。这一信息将进一步 我们对激活和激活的正常生理的理解 未激活的单核细胞，另外，希望能让我们 更合理地设计过继免疫治疗试验 纯化的自体细胞毒性单核细胞将被给予 癌症患者静脉注射。

This research study is designed to assess the trafficking pattern of autologous monocytes when given intravensously to humans. Monocytes will be removed from normal volunteers or from cancer patients by cytapheresis and purified by counter-current centrifugal elutriation. The purified monocytes will either be left at 4 degrees (normal monocytes) for 4 hours or be activated by exposure to recombinant human gamma interferon. The cells will be labeled with Indium-111 and infused intravenously back into the normal donor or patient, respectively. Normal donors or cancer patients will first be given an intravenous infusion of autologous normal monocytes; if no untoward reactions are noted, the donors or patients may receive infusions of autologous gamma interferon- activated monocytes four weeks later. Frequent blood samples will be withdrawn from the patient or donor over the ensuing 96 hours to determine the rate at which the infused cells equilibrate with the marginating pool of blood monocytes (if one exists), and to determine the rate at which these cells emigrate from the bloodstream to enter the reticuloendothelial system and other tissues. In addition, multiple regional scintigraphs will be obtained to determine if these labeled monocytes preferentially localize to any one organ system. This information will further our understanding of the normal physiology of activated and unactivated monocytes and, in addition, hopefully will allow us to more rationally design adoptive immunotherapy trials in which purified autologous cytotoxic blood monocytes will be given to cancer patients intravenously.